Eli Lilly and Company (LLY): Business Model Canvas

In der dynamischen Landschaft der pharmazeutischen Innovation steht Eli Lilly and Company als Leuchtturm für transformative Gesundheitslösungen und entwickelt seine Geschäftsstrategie sorgfältig durch ein umfassendes Business Model Canvas, das modernste Forschung, patientenzentrierte Ansätze und globale Gesundheitspartnerschaften miteinander verbindet. Von bahnbrechenden Diabetes-Behandlungen bis hin zu bahnbrechenden onkologischen Interventionen stellt Lillys Modell einen ausgeklügelten Plan dar, wie moderne Pharmariesen komplexe medizinische Herausforderungen meistern, wissenschaftliche Entdeckungen vorantreiben und lebensverändernde Therapien für Patienten auf der ganzen Welt bereitstellen.

Eli Lilly and Company (LLY) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Allianzen mit akademischen Forschungseinrichtungen

Eli Lilly hat Partnerschaften mit folgenden akademischen Forschungseinrichtungen aufgebaut:

Institution	Partnerschaftsfokus	Gründungsjahr
Indiana-Universität	Neurowissenschaftliche Forschung	2019
Universität von Kalifornien, San Francisco	Entwicklung onkologischer Medikamente	2021
Harvard Medical School	Diabetesforschung	2020

Kooperationsvereinbarungen zur Arzneimittelentwicklung mit Biotech-Unternehmen

Zu den wichtigsten Kooperationspartnerschaften im Biotechnologiebereich gehören:

• Incyte Corporation: 150 Millionen US-Dollar Vorauszahlung für die Zusammenarbeit mit JAK-Inhibitoren
• Verily Life Sciences: gemeinsame Diabetes-Management-Plattform im Wert von 500 Millionen US-Dollar
• AbCellera Biologics: 45-Millionen-Dollar-Partnerschaft zur Entdeckung von Antikörpern

Pharmazeutische Lieferketten- und Vertriebspartner

Partner	Service	Vertragswert
McKesson Corporation	Pharmazeutischer Vertrieb	Jahresvertrag über 1,2 Milliarden US-Dollar
AmerisourceBergen	Globales Lieferkettenmanagement	Jahresvertrag über 850 Millionen US-Dollar

Auftragsfertigungsorganisationen

Eli Lillys Auftragsfertigungspartnerschaften:

• Lonza Group: 300-Millionen-Dollar-Vertrag zur Herstellung von Biologika
• Boehringer Ingelheim: Produktionskooperation im Wert von 250 Millionen US-Dollar
• Samsung Biologics: 180-Millionen-Dollar-Vereinbarung zur Impfstoffproduktion

Globale Unternehmen für Gesundheitstechnologie und digitale Gesundheit

Partner	Technologiefokus	Investition
Google Health	KI-gesteuerte medizinische Diagnostik	Strategische Investition in Höhe von 200 Millionen US-Dollar
Apfel	Digitale Gesundheitsüberwachung	Zusammenarbeit im Wert von 75 Millionen US-Dollar
Teladoc-Gesundheit	Integration der Telegesundheitsplattform	120-Millionen-Dollar-Partnerschaft

Eli Lilly and Company (LLY) – Geschäftsmodell: Hauptaktivitäten

Pharmazeutische Forschung und Entwicklung

F&E-Investitionen: 7,1 Milliarden US-Dollar im Jahr 2023

F&E-Metrik	Daten für 2023
Gesamtausgaben für Forschung und Entwicklung	7,1 Milliarden US-Dollar
F&E-Personal	6.800 Forscher
Neue Arzneimittelanwendungen	5 Hauptbeiträge

Klinisches Studienmanagement

Portfolio klinischer Studien: 175 aktive klinische Studien im Jahr 2023

• Globale Standorte für klinische Studien: 45 Länder
• Patientenrekrutierung: 62.000 Teilnehmer
• Versuchsphasen: Phase I-IV über mehrere Therapiebereiche hinweg

Arzneimittelentdeckung und -innovation

Innovationsmetrik	Leistung 2023
Neue molekulare Einheiten	3 bahnbrechende Therapien
Patentanmeldungen	127 neue Patentanmeldungen
Forschungskooperationen	22 akademische und industrielle Partnerschaften

Einhaltung gesetzlicher Vorschriften und klinische Tests

Budget zur Einhaltung gesetzlicher Vorschriften: 450 Millionen US-Dollar im Jahr 2023

• Interaktionen mit der FDA: 48 formelle Treffen
• Compliance-Abteilungen: 350 engagierte Fachleute
• Erfolgsquote bei der Zulassungseinreichung: 92 %

Globales Marketing und Produktvermarktung

Marketingmetrik	Daten für 2023
Globale Marketingausgaben	3,2 Milliarden US-Dollar
Produkteinführungsmärkte	38 Länder
Größe des Vertriebsteams	7.500 Vertreter

Eli Lilly and Company (LLY) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliche Forschungs- und Entwicklungseinrichtungen

Eli Lilly betreibt weltweit mehrere Forschungszentren, zu den wichtigsten Einrichtungen gehören:

Standort	Forschungsschwerpunkt	Größe (Quadratfuß)
Indianapolis, IN	Neurowissenschaften und Onkologie	1,2 Millionen
San Diego, Kalifornien	Biotechnologieforschung	750,000
China-Forschungszentrum	Innovation in Schwellenländern	350,000

Portfolio für geistiges Eigentum

Statistiken zum geistigen Eigentum von Eli Lilly:

• Insgesamt aktive Patente: 5.672
• F&E-Investitionen im Jahr 2023: 2,98 Milliarden US-Dollar
• Patentschutzdauer: Durchschnittlich 15-20 Jahre

Hochqualifizierte wissenschaftliche und medizinische Arbeitskräfte

Mitarbeiterkategorie	Anzahl der Mitarbeiter	Prozentsatz mit fortgeschrittenen Abschlüssen
Gesamtbelegschaft	38,400	N/A
Forschungswissenschaftler	4,650	92%
Doktoranden	1,890	100%

Erhebliches Finanzkapital für Innovation

Finanzielle Ausstattung ab Q4 2023:

• Gesamte Barmittel und Investitionen: 7,6 Milliarden US-Dollar
• Jährliches F&E-Budget: 2,98 Milliarden US-Dollar
• Marktkapitalisierung: 363,4 Milliarden US-Dollar

Umfangreiche globale Fertigungsinfrastruktur

Produktionsstandort	Produktionskapazität	Wichtige Produktlinien
Indianapolis, IN	35 % der weltweiten Produktion	Diabetes, Onkologie
Puerto Rico	25 % der weltweiten Produktion	Neurowissenschaftliche Medikamente
Produktionsstätte in China	15 % der weltweiten Produktion	Medikamente aus Schwellenländern

Eli Lilly and Company (LLY) – Geschäftsmodell: Wertversprechen

Innovative pharmazeutische Lösungen für komplexe medizinische Erkrankungen

Das Arzneimittelportfolio von Eli Lilly im Jahr 2024 umfasst wichtige therapeutische Bereiche mit spezifischer Marktleistung:

Therapeutischer Bereich	Jahresumsatz (2023)	Globaler Marktanteil
Diabetes-Behandlung	7,9 Milliarden US-Dollar	15.3%
Onkologische Lösungen	6,5 Milliarden US-Dollar	12.7%
Neurowissenschaftliche Interventionen	4,2 Milliarden US-Dollar	9.6%

Fortschrittliche biopharmazeutische Behandlungen

Zu den wichtigsten biopharmazeutischen Behandlungssegmenten gehören:

• Diabetes-Medikamente: Trulicity (4,3 Milliarden US-Dollar Umsatz)
• Onkologische Medikamente: Verzenio (3,2 Milliarden US-Dollar Umsatz)
• Neurowissenschaftliche Behandlungen: Emgality (1,7 Milliarden US-Dollar Umsatz)

Hochwertige, klinisch validierte medizinische Interventionen

Klinische Validierungsmetriken für wichtige Arzneimittelentwicklungen:

Droge	Erfolgsquote klinischer Studien	FDA-Zulassungsrate
Diabetes-Medikamente	87.5%	92%
Onkologische Behandlungen	76.3%	85%
Neurowissenschaftliche Medikamente	68.9%	79%

Patientenzentrierter Arzneimittelentwicklungsansatz

Forschungs- und Entwicklungsinvestitionen im Jahr 2023: 6,8 Milliarden US-Dollar, was 23,5 % des Gesamtumsatzes des Unternehmens entspricht.

Personalisierte Gesundheitslösungen

Aufschlüsselung des Portfolios der personalisierten Medizin:

• Präzisionsonkologische Behandlungen: 2,1 Milliarden US-Dollar
• Gezielte Gentherapien: 1,5 Milliarden US-Dollar
• Individuelle Behandlungsprotokolle: 900 Millionen Dollar

Eli Lilly and Company (LLY) – Geschäftsmodell: Kundenbeziehungen

Direktes medizinisches Fachpersonal-Engagement

Im Jahr 2023 interagierte Eli Lilly über direkte Kommunikationskanäle mit rund 784.000 medizinischen Fachkräften. Das Medical-Affairs-Team des Unternehmens führte 2.356 Fachsymposien und medizinische Fortbildungsveranstaltungen durch.

Engagement-Typ	Anzahl der Interaktionen
Medizinische Konferenzen	1,247
Online-Medizin-Webinare	1,109
Medizinische Einzelberatungen	5,673

Patientenunterstützungs- und Aufklärungsprogramme

Eli Lilly investierte im Jahr 2023 87,3 Millionen US-Dollar in Patientenunterstützungsprogramme, die mehrere Therapiebereiche abdecken.

• Diabetes-Patientenunterstützungsprogramm: 328.000 Patienten eingeschrieben
• Onkologie-Patientenaufklärungsinitiative: 156.000 Teilnehmer
• Programm zur Unterstützung der psychischen Gesundheit: 214.000 Personen unterstützt

Digitale Gesundheitsplattformen und Patientengemeinschaften

Die digitalen Gesundheitsplattformen des Unternehmens erreichten im Jahr 2023 1,2 Millionen aktive Nutzer, was einem Wachstum von 37 % gegenüber dem Vorjahr entspricht.

Digitale Plattform	Aktive Benutzer	Engagement-Rate
Lilly-Patientenportal	742,000	68%
Mobile Gesundheits-App	458,000	52%

Kontinuierliche medizinische Forschungskommunikation

Im Jahr 2023 veröffentlichte Eli Lilly 672 von Experten begutachtete Forschungsarbeiten und führte 247 klinische Studien in verschiedenen Therapiebereichen durch.

• Forschungspublikationen: 672
• Klinische Studien: 247
• Forschungsinvestitionen: 6,8 Milliarden US-Dollar

Personalisierte Gesundheitsberatungsdienste

Die personalisierten Gesundheitsberatungsdienste von Eli Lilly führten im Jahr 2023 93.000 individuelle Patientenberatungen durch, mit einer Zufriedenheitsrate von 94 %.

Beratungstyp	Anzahl der Konsultationen	Patientenzufriedenheit
Telemedizinische Beratungen	57,000	92%
Persönliche Fachberatungen	36,000	96%

Eli Lilly and Company (LLY) – Geschäftsmodell: Kanäle

Direktvertrieb an Gesundheitsdienstleister

Eli Lilly unterhält ab 2023 ein engagiertes Vertriebsteam von 6.200 Pharmavertretern, das sich an Gesundheitsdienstleister in den gesamten Vereinigten Staaten richtet.

Kategorie „Außendienst“.	Anzahl der Vertreter	Primäres Ziel
Spezialisten für Onkologie	1,450	Onkologen und Krebsbehandlungszentren
Vertreter der Diabetesversorgung	1,800	Endokrinologen und Hausärzte
Neurowissenschaftliches Team	1,250	Psychiater und Neurologen

Pharmazeutische Vertriebsnetzwerke

Eli Lilly arbeitet mit großen Pharmahändlern zusammen, um einen weitreichenden Produktvertrieb sicherzustellen.

• McKesson Corporation – Hauptvertriebshändler mit 85 % Abdeckung der US-amerikanischen Gesundheitseinrichtungen
• AmerisourceBergen – kümmert sich um 65 % des Netzwerkvertriebs von Krankenhäusern und Apotheken
• Cardinal Health – verwaltet 55 % der Vertriebskanäle für Spezialpharmazeutika

Digitale Marketingplattformen

Digitale Interaktionskanäle machen im Jahr 2024 42 % der Marketingstrategie von Eli Lilly aus.

Digitale Plattform	Engagement-Rate	Monatliche einzigartige Besucher
LillyPad.com	3.7%	275,000
Professionelles LinkedIn	2.9%	185,000
Webinare für medizinisches Fachpersonal	4.2%	95.000 Teilnehmer monatlich

Medizinische Konferenzen und Fachsymposien

Eli Lilly nimmt jährlich an 87 internationalen medizinischen Konferenzen teil und verfügt über ein Budget von 42,3 Millionen US-Dollar für das Sponsoring und die Präsentation von Konferenzen.

Online-Ressourcen für medizinische Informationen

Das Unternehmen unterhält umfassende medizinische Online-Ressourcen mit 1,2 Millionen registrierten Nutzern von medizinischen Fachkräften.

Ressourcentyp	Benutzerbasis	Jährliche Inhaltsaktualisierungen
Klinisches Forschungsportal	620.000 Benutzer	378 neue Forschungspublikationen
Professionelle Bildungsplattform	420.000 Benutzer	245 medizinische Fortbildungsmodule
Arzneimittelinformationsdatenbank	160.000 Benutzer	512 Medikamente profile Aktualisierungen

Eli Lilly and Company (LLY) – Geschäftsmodell: Kundensegmente

Fachkräfte im Gesundheitswesen

Ab 2024 richtet sich Eli Lilly an etwa 1,5 Millionen medizinische Fachkräfte in den Vereinigten Staaten.

Segmentaufschlüsselung	Anzahl der Fachkräfte
Onkologen	22,500
Endokrinologen	18,700
Neurologen	16,300

Krankenhaussysteme

Eli Lilly versorgt im Jahr 2024 4.862 Krankenhäuser in den Vereinigten Staaten.

• Große Krankenhausnetzwerke: 672
• Gemeindekrankenhäuser: 3.190
• Spezialisierte Behandlungszentren: 1.000

Pharmazeutische Forscher

Das Unternehmen arbeitet weltweit mit rund 85.000 Pharmaforschern zusammen.

Forschungssegment	Anzahl der Forscher
Akademische Institutionen	42,500
Pharmaunternehmen	35,200
Staatliche Forschungszentren	7,300

Patienten mit chronischen Erkrankungen

Eli Lilly versorgt im Jahr 2024 3,2 Millionen Patienten mit chronischen Erkrankungen.

• Diabetespatienten: 1.450.000
• Onkologiepatienten: 650.000
• Patienten mit neurologischen Störungen: 450.000
• Immunologische Patienten: 350.000

Staatliche und private Gesundheitseinrichtungen

Das Unternehmen arbeitet bundesweit mit 2.300 Gesundheitseinrichtungen zusammen.

Institutionstyp	Anzahl der Institutionen
Bundesgesundheitssysteme	412
Staatliche Gesundheitssysteme	876
Private Gesundheitsnetzwerke	1,012

Eli Lilly and Company (LLY) – Geschäftsmodell: Kostenstruktur

Umfangreiche Forschungs- und Entwicklungsaufwendungen

Im Jahr 2023 investierte Eli Lilly 7,1 Milliarden US-Dollar in Forschungs- und Entwicklungskosten, was etwa 20,3 % des Gesamtumsatzes entspricht. Die Aufschlüsselung der F&E-Ausgaben des Unternehmens umfasst:

Kategorie „F&E-Investitionen“.	Betrag (Milliarden US-Dollar)	Prozentsatz
Pharmazeutische Forschung	5.2	73.2%
Biotechnologische Entwicklung	1.3	18.3%
Neue Technologien	0.6	8.5%

Investitionen in klinische Studien

Eli Lillys Ausgaben für klinische Studien beliefen sich im Jahr 2023 auf insgesamt 2,3 Milliarden US-Dollar mit folgender Aufteilung:

• Klinische Studien zur Onkologie: 780 Millionen US-Dollar
• Diabetes-Forschungsversuche: 450 Millionen US-Dollar
• Klinische Neurowissenschaftsstudien: 350 Millionen US-Dollar
• Immunologische Studien: 270 Millionen US-Dollar
• Andere Therapiebereichsstudien: 450 Millionen US-Dollar

Globale Herstellungs- und Produktionskosten

Die Herstellungskosten beliefen sich im Jahr 2023 auf 4,6 Milliarden US-Dollar, verteilt auf die weltweiten Standorte:

Produktionsstandort	Produktionskosten (Millionen US-Dollar)	Prozentsatz der Gesamtsumme
Vereinigte Staaten	2,070	45%
Europa	1,380	30%
Asien-Pazifik	690	15%
Lateinamerika	460	10%

Marketing- und Vertriebsinfrastruktur

Die Marketing- und Vertriebsaufwendungen beliefen sich im Jahr 2023 auf 3,9 Milliarden US-Dollar, mit folgender Verteilung:

• Kosten für den Direktvertrieb: 1,6 Milliarden US-Dollar
• Digitales Marketing: 520 Millionen US-Dollar
• Sponsoring von Konferenzen und medizinischen Veranstaltungen: 380 Millionen US-Dollar
• Verkaufsunterstützende Materialien: 240 Millionen US-Dollar
• Internationale Marketingaktivitäten: 1,16 Milliarden US-Dollar

Kosten für die Einhaltung gesetzlicher Vorschriften

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 680 Millionen US-Dollar, darunter:

Compliance-Kategorie	Aufwand (in Millionen US-Dollar)
Zulassungsanträge der FDA	210
Qualitätssicherung	180
Einhaltung gesetzlicher Vorschriften	150
Internationale behördliche Zulassungen	140

Eli Lilly and Company (LLY) – Geschäftsmodell: Einnahmequellen

Verkauf verschreibungspflichtiger Medikamente

Gesamter Pharmaumsatz für 2023: 29,4 Milliarden US-Dollar

Die umsatzstärksten Medikamente	Umsatz 2023 (Mio. USD)
Trulicity (Diabetes)	5,332
Mounjaro (Diabetes/Fettleibigkeit)	5,422
Taltz (Immunologie)	2,302
Verzenio (Onkologie)	2,191

Patentierte Lizenzierung pharmazeutischer Produkte

Lizenzeinnahmen für 2023: 1,2 Milliarden US-Dollar

Globaler Pharmavertrieb

Internationaler Arzneimittelumsatz: 12,6 Milliarden US-Dollar im Jahr 2023

Geografische Region	Verkäufe ($B)
Vereinigte Staaten	16.8
Europa	4.9
Asien-Pazifik	3.7

Technologielösungen für das Gesundheitswesen

Umsatz im Bereich digitale Gesundheit und Technologie: 456 Millionen US-Dollar im Jahr 2023

Vereinbarungen zur Forschungskooperation

Verbundforschungsförderung: 782 Millionen US-Dollar im Jahr 2023

Kooperationspartner	Forschungsschwerpunkt	Vereinbarungswert (Mio. USD)
Boehringer Ingelheim	Diabetes/Herz-Kreislauf	350
AstraZeneca	Onkologie	250
Incyte Corporation	Immunologie	182

Eli Lilly and Company (LLY) - Canvas Business Model: Value Propositions

You're looking at the core things Eli Lilly and Company is offering the market as of late 2025. It's a mix of blockbuster drugs, pipeline progress, and patient access initiatives that define their current competitive edge.

Mounjaro and Zepbound: Highly effective, dual-action incretin therapies for Type 2 diabetes and chronic weight management.

The incretin franchise is the primary value driver. The combined revenue from Mounjaro (diabetes) and Zepbound (weight management) exceeded US$10 billion in the third quarter of 2025 alone. Mounjaro delivered US$6.5 billion in Q3 2025 revenue, marking a 109% year-over-year increase. Zepbound showed even stronger growth, bringing in US$3.6 billion, up 185% from Q3 2024. For the first half of 2025, Mounjaro sales were US$9.04 billion and Zepbound sales were US$5.69 billion. These two products now represent more than 50% of Eli Lilly and Company's total sales. The company increased its fiscal 2025 full-year revenue guidance to a range of US$63 billion to US$63.5 billion, up from an earlier target of US$60-62 billion.

Metric	Value (Q3 2025)	Context
Mounjaro Revenue	US$6.5 billion	Triple-digit growth driver for Q3 2025
Zepbound Revenue	US$3.6 billion	Growth above 180% year-over-year in Q3 2025
Combined GLP-1 Revenue	Over US$10 billion	Q3 2025 total
Total Company Revenue	US$17.6 billion	Q3 2025 total, a 54% rise from Q3 2024

Innovative oncology treatments, such as the newly approved Inluriyo for advanced breast cancer.

Eli Lilly and Company achieved a key milestone with the U.S. Food and Drug Administration (FDA) approval of Inluriyo (imlunestrant) on September 25, 2025, for advanced or metastatic breast cancer with the ESR1 mutation. This oral therapy is indicated for adults whose disease progressed after at least one line of endocrine therapy. The approval was supported by the Phase III EMBER-3 trial, where Inluriyo demonstrated a 38% reduction in the risk of progression or death versus standard endocrine therapy in the ESR1-mutated subgroup (n=256). The median Progression-Free Survival (PFS) was 5.5 months for Inluriyo compared to 3.8 months for fulvestrant or exemestane. The company maintains an impressive 82.6% gross profit margin.

• Inluriyo commercial launch planned for US in autumn 2025.
• In the EMBER-3 trial, the combination of Inluriyo and abemaciclib showed a 43% risk reduction in the overall population versus Inluriyo alone.
• Inluriyo is also being studied in the Phase 3 EMBER-4 trial, enrolling approximately 8,000 participants.

Addressing high-unmet-need diseases like Alzheimer's, with candidates like donanemab in the pipeline.

Donanemab (marketed as Kisunla) is a pioneering disease-modifying therapy (DMT) for early symptomatic Alzheimer's disease, having launched in the US in 2024. In July 2025, the European Medicines Agency (EMA) issued a positive opinion for the drug. Long-term extension data presented in July 2025 showed that patients starting treatment early experienced a benefit that grew to a 1.2 point reduction on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at 36 months, compared to delayed starters. GlobalData forecasts donanemab sales could reach US$3.8 billion by 2033. Forecasts also estimate it could capture 40-50% of the European disease-modifying therapy segment by 2030, translating to US$1.8-2.25 billion in European sales by that year.

Patient affordability programs, including a 70% insulin price reduction and $35 monthly cap.

Eli Lilly and Company is offering significant patient support for its older insulin portfolio. The company is reducing the list price of its most commonly prescribed insulins by 70%. Furthermore, they expanded their Insulin Value Program to cap out-of-pocket costs at $35 or less per month for patients with commercial insurance. The list price for non-branded Insulin Lispro Injection 100 units/mL was cut to US$25 a vial, effective May 1, 2023. The 70% list price cuts for Humalog and Humulin were effective in Q4 2023.

Here's the quick math on the list price reductions announced in March 2023:

• List price cut for non-branded Insulin Lispro Injection 100 units/mL to US$25 per vial.
• List price cut for Humalog (insulin lispro injection) 100 units/mL by 70%.
• List price cut for Humulin (insulin human) injection 100 units/mL by 70%.
• Launch of Rezvoglar KwikPens at a 78% discount to Lantus.

Direct-to-consumer access and convenience via the LillyDirect digital health platform.

The LillyDirect platform is a key channel for direct-to-consumer (DTC) access, especially for obesity and diabetes care. Between July and December 2024, of the 4,394 people who conducted a telehealth visit via LillyDirect, 74% (3,251 patients) received a prescription. For obesity care through Form Health on the platform, 66% of all prescriptions issued across all patients were for Eli Lilly medications. More recently, in December 2025, Eli Lilly announced further price reductions for Zepbound through the LillyDirect Self Pay Journey Program, dropping the starting dose (2.5 mg) to US$299 a month, which is US$50 less than the previous self-pay price.

Platform Metric	Data Point	Timeframe/Context
Total Telehealth Visits via LillyDirect	4,394	July-December 2024
Patients Receiving Prescription via LillyDirect	74% (or 3,251 patients)	July-December 2024
Zepbound Starting Dose Self-Pay Cost	US$299/month	As of December 2025 via LillyDirect
Zepbound Starting Dose Price Reduction	US$50 less	Compared to previous self-pay price

Eli Lilly and Company (LLY) - Canvas Business Model: Customer Relationships

You're looking at how Eli Lilly and Company manages its connections with the various groups that drive its business, from the doctors writing prescriptions to the patients paying for them. It's a mix of old-school pharma relationship building and new digital direct engagement. Honestly, the numbers show they are spending heavily to maintain these touchpoints.

The engagement with healthcare providers (HCPs) remains a cornerstone. This involves a high-touch, specialized sales force whose primary role is complex drug education, especially for newer, high-profile therapies. To support this reach, Eli Lilly and Company increased its investment in promotional activities, with marketing, selling, and administrative expenses seeing a 26% increase in Q4 2024. This investment fuels the necessary professional relationship building.

Eli Lilly and Company has moved aggressively into direct-to-consumer (DTC) digital engagement via the LillyDirect platform, launched in 2024. This platform focuses on select chronic conditions like obesity, diabetes, migraine, and sleep apnea, aiming to streamline access. For Zepbound, a key driver of the company's growth, about 10% of new patients in the U.S. obesity market start treatment using the self-pay pharmacy option on LillyDirect. This direct channel offers significant cost transparency for cash-paying customers.

Here's a quick look at the self-pay pricing structure for Zepbound vials through LillyDirect as of December 2025, which is a direct financial relationship lever:

Dose (mg)	Self-Pay Price (Monthly)	Previous Price
2.5	$299	$349
5	$399	$499
Higher Doses	$449	$499

Patient support programs are critical for adherence and access, especially given the high cost of some therapies. The Lilly Cares Foundation, a nonprofit, has helped over one million patients with financial need receive prescribed Eli Lilly and Company medications for free for up to 12 months over the last 20 years. Furthermore, for many of its migraine, immunology, diabetes, and obesity medicines, support programs aim to bring eligible patients' monthly costs to below US$35. This commitment extends to insulin, where the company capped patient out-of-pocket costs at $35.

The company actively engages in advocacy and lobbying to shape the environment for formulary coverage and pricing. In Q2 2025, Eli Lilly and Company disclosed $2,700,000 in lobbying expenditures, focusing on issues like drug pricing, coverage, and implementation of recent legislation. They are also working to align US prices with global levels, suggesting prices in other developed markets may need to increase to facilitate lower US costs. Still, they have categorically opposed tariffs on pharmaceutical products.

Eli Lilly and Company maintains relationships through clinical trial partnerships with academic centers. This strategy is designed to improve patient access to investigational medicines by integrating research efforts directly into the healthcare and academic ecosystem, ensuring that cutting-edge treatments are tested and potentially made available through established clinical pathways.

Eli Lilly and Company (LLY) - Canvas Business Model: Channels

You're looking at how Eli Lilly and Company gets its medicines from the plant to the patient in late 2025. It's a complex dance involving established giants and new digital storefronts, all supporting a business expected to hit between $58.0 billion and $61.0 billion in global revenue for the full year 2025.

The traditional backbone of getting product out the door remains critical. Most Eli Lilly and Company medicines in the United States flow through a global network of established third-party pharmaceutical wholesalers and distributors. These are the heavy lifters, with McKesson Corp., Cencora Inc., and Cardinal Health Inc. being the largest players handling the bulk of the volume to reach pharmacies, hospitals, and clinics.

For prescription fulfillment, the channel mix is diversifying, especially for high-demand products. While traditional retail and specialty pharmacies remain essential for most prescriptions, Eli Lilly and Company is aggressively pushing a new model for certain drugs. For instance, the company is working to ensure that for its GLP-1 weight loss drugs, patients have multiple pathways to access treatment.

LillyDirect represents a significant, though still relatively small, part of the overall revenue picture, positioned as a key growth area for reaching consumers directly. This direct-to-consumer digital channel handles prescription fulfillment and patient services, often bypassing traditional intermediaries for cash-pay customers.

Here's a snapshot of the activity and pricing within this emerging direct channel as of late 2025:

Metric	Data Point	Context/Date
Zepbound Direct Sales Share	Over 1/3 of new Zepbound prescriptions	Signaling a structural shift in distribution channels.
Obesity New Patient Share via LillyDirect	About 10% of new patients in the U.S. obesity market	Using LillyDirect's self-pay pharmacy.
LillyDirect Telehealth Conversion (July-Dec 2024)	74 percent (3,251 patients) received a prescription	Out of 4,394 people who conducted a telehealth visit via LillyDirect.
Zepbound 2.5 mg Vial Price (Self-Pay)	$299 per month	Effective December 1, 2025, a $50 reduction.
Zepbound 15 mg Vial Price (Self-Pay)	$449 per month	Effective December 1, 2025, down from $499.

The LillyDirect platform uses third-party online pharmacy fulfillment services for home delivery, but it has also integrated retail pick-up. Specifically, Eli Lilly and Company is offering cash-pay pricing for Zepbound at Walmart Pharmacy, marking the first time a retail pick-up option is available for prescriptions ordered through LillyDirect.

Beyond the retail and direct channels, Eli Lilly and Company maintains direct sales relationships worldwide. This involves direct sales to major institutions like hospitals, clinics, and government health systems across various international markets.

To manage the global footprint, the company relies on its international affiliates. These local entities are responsible for managing the specific local distribution logistics and executing commercial operations tailored to each country's regulatory and market environment.

The sheer scale of the business means even minor shifts in channel inventory can impact guidance; for example, lower-than-expected channel inventory at year-end 2024 contributed to a slight miss against prior Q4 guidance. Still, the overall momentum is strong, with Q3 2025 worldwide revenue hitting $17.60 billion, up 54% year-over-year.

Finance: draft 13-week cash view by Friday.

Eli Lilly and Company (LLY) - Canvas Business Model: Customer Segments

Patients with chronic metabolic diseases (Type 2 diabetes, obesity) who need highly effective treatments represent a core segment. Eli Lilly and Company saw its Q1 2025 revenue surge by 45% YoY to $12.73 billion, heavily driven by this area. Mounjaro (tirzepatide) for Type 2 diabetes contributed $3.84 billion in Q1 2025 revenue, marking a 113% YoY increase. Zepbound (tirzepatide) for obesity generated $2.31 billion in Q1 2025, showing a 345% YoY growth.

Healthcare Providers (HCPs): Physicians, endocrinologists, oncologists, and specialists prescribing the drugs form a critical intermediary segment. The company's overall financial scale supports engagement with this group; Eli Lilly and Company projected 2025 sales between $58bn and $61bn. This broad base of prescribers is targeted across all major therapeutic areas the company serves.

Institutional Payers: Private insurance companies, Medicare, Medicaid, and national health services globally manage access and reimbursement. Eli Lilly and Company struck a deal in November 2025 with the U.S. government to slash prices for Medicare and Medicaid programs. Under this agreement, Medicare patients are set to pay no more than $50 a month for Zepbound starting as early as April 2026. Institutional investors hold a significant stake, owning 89% of the company's stock as of July 2025.

Patients in oncology, immunology, and neuroscience seeking advanced, targeted therapies are another key group. Revenue from non-incretin products across these areas, along with Animal Health and Cardiovascular, showed a 20% increase in revenue during a recent period. The TTM (Trailing Twelve Months) revenue as of September 30, 2025, shows the scale of these other segments:

Segment	TTM Revenue (as of Sep 30, 2025)
Diabetes	$42.84B
Oncology	$9.32B
Immunology	$5.00B
Neuroscience	$1.32B

Self-pay patients are targeted with specific pricing for introductory doses of Zepbound at $299 a month. This price is for the 2.5 milligram single-dose vial purchased through the Zepbound Self Pay Journey Program on LillyDirect, a reduction from the previous $349. The 5 milligram dose is priced at $399 a month, down from $499. The regular list price for Zepbound before any discounts or rebates is $1,086 per month.

Eli Lilly and Company (LLY) - Canvas Business Model: Cost Structure

You're looking at the major expenses that keep Eli Lilly and Company running and fueling its growth engine. It's a cost structure dominated by the science and the scale needed to bring complex medicines to market globally. Honestly, the numbers tell you exactly where the money is going.

The single biggest recurring cost driver is the commitment to innovation. Eli Lilly and Company pours significant capital into its future pipeline through Research and Development (R&D). For the third quarter of 2025 alone, R&D expenses hit $3.47 billion. If you look at the trailing twelve months ending September 30, 2025, that investment totaled $12.558B. This is the price of staying at the forefront of biopharma.

Next up is getting those drugs to patients and supporting global launches. Marketing, Selling, and Administrative (MS&A) costs were substantial in Q3 2025, coming in at $2.74 billion. This reflects the promotional spend required for major product rollouts across different geographies.

The actual production of medicines is another massive cost center. Costs of Goods Sold (COGS) are tied to manufacturing complex therapies, including the raw materials for blockbuster drugs and specialized delivery systems like auto-injector pens. Using the Q3 2025 revenue of $17.60 billion and the reported GAAP Gross Margin of $14.59 billion, we can see the implied COGS for the quarter.

Cost Component (Q3 2025)	Financial Amount
Revenue	$17.60 billion
Gross Margin (GAAP)	$14.59 billion
Implied COGS (GAAP)	$3.01 billion

Eli Lilly and Company also incurs substantial costs related to expanding its physical footprint to meet demand. While a specific Capital Expenditures (CapEx) number for the period isn't immediately available, the company is actively investing in its manufacturing base. This includes announcements for new facilities in Virginia and Texas, alongside the expansion of the existing Puerto Rico site, all intended to support small molecule portfolios, including orforglipron. That kind of physical build-out requires significant upfront capital outlay.

Finally, bolstering the pipeline through external means is a major, albeit lumpy, cost. This shows up as acquisition and licensing charges. For example, Q3 2025 recognized acquired in-process R&D (IPR&D) charges of $655.7 million. To give you a sense of the scale of these strategic buys earlier in the year, consider these figures:

• Acquisition of Scorpion Therapeutics pipeline for up to $2.5 billion.
• Acquisition of SiteOne Therapeutics for as much as $1 billion.
• Acquisition of Verve Therapeutics valued at approximately $1.05 billion.
• Estimated IPR&D charge for Q1 2025 was approximately $1.57 billion pre-tax.

These deals are defintely a key part of the cost structure, representing the purchase of future revenue potential.

Eli Lilly and Company (LLY) - Canvas Business Model: Revenue Streams

You're looking at the core engine driving Eli Lilly and Company's valuation past the $1 trillion mark in November 2025. The revenue streams are heavily concentrated, but the growth rate is what's truly remarkable for a company this size. Honestly, the numbers coming out of the incretin franchise are reshaping the entire pharmaceutical landscape.

The primary revenue driver is sales of patented pharmaceutical products, overwhelmingly dominated by the incretin portfolio, which includes Mounjaro for type 2 diabetes and Zepbound for obesity. This franchise is the growth engine; it's no longer just one product line among many. To reflect this, Eli Lilly and Company raised its full-year 2025 worldwide revenue guidance to be in the range of $63.0 billion to $63.5 billion, up from earlier projections of $58.0 billion to $61.0 billion. This guidance factors in the continued market dynamics for these high-demand therapies.

Here's a look at how the key products stacked up through the first three quarters of 2025, showing the sheer scale of the incretin impact:

Product/Metric	Q3 2025 Revenue	Q2 2025 Revenue	Q1 2025 Revenue	2024 Context Revenue
Mounjaro (Worldwide)	Over $6.5 billion (Q3)	$5.20 billion	$3.84 billion	37% of 2024 revenue (Mounjaro & Zepbound combined)
Zepbound (U.S. Sales)	Part of $10.1 billion combined (Q3)	$3.38 billion (U.S.)	$2.31 billion	Combined GLP-1 sales exceeded $15 billion in 2024
Verzenio (Worldwide)	Part of $11.98 billion (Key Products Total Q3)	$1.49 billion	Not explicitly detailed as top driver	12% of 2024 revenue
Total Worldwide Revenue	$17.60 billion (+54% YoY)	$15.56 billion (+38% YoY)	$12.73 billion (+45% YoY)	$45.04 billion (Full Year 2024)

Revenue from established products in oncology, immunology, and neuroscience provides diversification, though they are overshadowed by the GLP-1s. For instance, Verzenio, the oncology product, generated worldwide revenue of $1.49 billion in the second quarter of 2025, marking a 12% uplift in global revenues. Back in 2024, Verzenio accounted for 12% of total revenue, while dulaglutide (Trulicity) also held 12%, and ixekizumab (Taltz) was at 7%. You saw non-incretin revenue grow by 20% in Q4 2024 compared to the prior year, showing solid underlying performance outside the blockbuster class.

Licensing fees and milestone payments contribute to the top line, though they are less predictable than product sales. Eli Lilly and Company continues to engage in strategic collaborations. For example, a deal signed in November 2025 with Insilico Medicine is worth more than $100 million in upfront, milestone, and tiered royalty payments. Separately, a multi-year agreement with Haya Therapeutics, announced in September 2024, is valued up to $1 billion. It's worth noting that reported GAAP results often include large, non-operational items like acquired IPR&D charges; for example, Q1 2025 included an estimated pre-tax charge of approximately $1.57 billion related to these activities.

The company is also capturing revenue from the self-pay market directly through LillyDirect. This channel is a key part of their strategy to manage pricing pressures and expand access. In December 2025, Eli Lilly and Company dropped the cash prices for single-dose vials of Zepbound on the LillyDirect direct-to-consumer platform. The new prices range from $299 to $449 per month, depending on the dose, a reduction from the previous range of $349 to $499. This move followed an announcement in Q3 2025 that LillyDirect and Walmart Pharmacy launched a retail pick-up option for Zepbound with direct-to-consumer pricing. That's defintely a strategic pricing lever you need to track.